AB
The startup develops infectious disease vaccines utilizing polymersome technology, which enhances immune response and improves manufacturability. This approach provides a stable, easy-to-store vaccine solution that eliminates the need for a complex cold chain, addressing challenges in vaccine distribution and accessibility.
Updated 3 months ago
Funding
$4.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops infectious disease vaccines utilizing polymersome technology, which enhances immune response and improves manufacturability. This approach provides a stable, easy-to-store vaccine solution that eliminates the need for a complex cold chain, addressing challenges in vaccine distribution and accessibility.